# Solasta Ventures

> Solasta Ventures is a VC fund in Boston backing Biotechnology and Health Care. See 37 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 37
- Last investment: Sep 2025
- Lead investor: 5%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/solasta-ventures/about/
- Website: https://solasta-ventures.com/

Solasta Ventures is a VC fund in Boston focused on Biotechnology and Health Care. Solasta Ventures is investing in healthcare and life sciences for a brighter future.

## Contacts

5 contacts available for Solasta Ventures. Shizune tracks 5 team members at Solasta Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/solasta-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 21 | 57% |
| Health Care | 18 | 49% |
| Therapeutics | 16 | 43% |
| Medical | 8 | 22% |
| Biopharma | 5 | 14% |

39 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 12 | 32% |
| Series A | 7 | 19% |
| Series C | 6 | 16% |
| Funding Round | 4 | 11% |
| Post-IPO Equity | 3 | 8% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 27 | 73% |
| Canada | 1 | 3% |
| New Zealand | 1 | 3% |
| South Korea | 1 | 3% |
| United Kingdom | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Carl Choi | Prinipal | 0 | — |
| Derek Yoon | President & CEO | 0 | https://shizune.co/investors/profile/derek-yoon |
| Michael Jeon | Managing Partner | 1 | — |
| Nia Julian | Executive Assistant | 0 | — |
| William Hahn | Chair & Scientific Advisory Board | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Summer Robotics | Summer Robotics is a machine vision company that builds robotic perception software for the industrial manufacturing and mobility markets.Summer Robotics has developed a perception platform that enables robots to work in more complex and fast moving environments than previously possible. We are working with established partners to build the nextgeneration of robotic measurement and manufacturing capabilities that will significantly improve quality and productivity. Summer Robotics' mission is to give all robotic systems superhuman perception and response capabilities, enabling entirely new and valuable applications in markets such as manufacturing and mobility. |  | Series A | Sep 30, 2025 |  |
| Ensoma | Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. | $53M |  | Sep 22, 2025 |  |
| Maxion Therapeutics | Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets. | $75.3M | Series A | Mar 17, 2025 |  |
| Axonis Therapeutics | Axonis translates breakthrough regeneration research to groundbreaking paralysis therapy, to transform the lives of spinal cord injury patients. | $115M | Series A | Oct 30, 2024 |  |
| DAAN Biotherapeutics | DAAN Biotherapeutics develops novel treatments for cancer patients. The company conducts cancer treatment research and development, including cell therapies, antibodies, and small molecule inhibitors. | $17.2M | Series A | Jan 25, 2024 |  |
| EvolveImmune Therapeutics | EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases. | $37.4M | Venture - Series Unknown | Nov 16, 2023 |  |
| ReCode Therapeutics | ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $50M | Series B | Sep 19, 2023 |  |
| Boxhub | Boxhub combines e-commerce and logistics, revolutionizing the way shipping containers are traded, transported, and used. By leveraging tech infrastructure and automation, we make the experience for our customers and suppliers faster, cheaper, and more transparent. | $12.4M | Series A | Jun 28, 2023 |  |
| Prime Roots | Feeding people and the planet with 100% plant-based powerhouse protein! Joshua Nixon and Kimberlie Le founded Terramino in 2017 that later became Prime Roots. It has its headquarters in Berkeley, California. | $30M | Series B | May 15, 2023 |  |
| Prime Roots | Feeding people and the planet with 100% plant-based powerhouse protein! Joshua Nixon and Kimberlie Le founded Terramino in 2017 that later became Prime Roots. It has its headquarters in Berkeley, California. | $30M | Series B | May 15, 2023 |  |

10 of 37 investments shown.

## Co-investors
- [MRL Ventures Fund](https://shizune.co/investors/profile/mrl-venture-fund) — VC Fund, 6 deals together
- [Takeda Ventures](https://shizune.co/investors/profile/takeda-ventures) — VC Fund, 6 deals together
- [Agent Capital](https://shizune.co/investors/profile/agent-capital) — VC Fund, 5 deals together
- [HealthCap](https://shizune.co/investors/profile/healthcap) — VC Fund, 5 deals together
- SymBiosis LLC — VC Fund, 5 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Solasta Ventures invest in?

Solasta Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 37 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Solasta Ventures?

Public channels for Solasta Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Solasta Ventures?

The team at Solasta Ventures includes Carl Choi (Prinipal), Derek Yoon (President & CEO) and Michael Jeon (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co